“Eligible healthcare providers can realize substantial financial benefits from the discounts that drug manufacturers are required to provide on outpatient drugs under the 340B Drug Pricing Program. Because the program is complicated, internal audit can help assure that compliance risks are properly identified and managed.”

Read more from this article by Draffin Tucker Manager Matt Atkins, in the 2020 Summer Edition of the Association of Healthcare Internal Auditors magazine, New Perspectives.

*This article was reprinted with permission from the 2020 Summer Edition of New Perspectives Magazine published by the Association of Healthcare Internal Auditors, ahia.org.